Add Yahoo as a preferred source to see more of our stories on Google. Amylyx Pharmaceuticals announced Friday that its drug for amyotrophic lateral sclerosis, or ALS, called Relyvrio, did not show ...
The news last week that a Phase 3 trial of Amylyx Pharmaceuticals’ amyotrophic lateral sclerosis drug — marketed as Relyvrio — failed to benefit patients compared to placebo hit the ALS patient ...
When the results of the first-ever platform trial for amyotrophic lateral sclerosis (ALS) were published this February, the headlines might have seemed disappointing: four experimental drugs failed to ...
(CNN) — Amylyx Pharmaceuticals announced Friday that its drug for amyotrophic lateral sclerosis, or ALS, called Relyvrio, did not show significant benefit in a large clinical trial and may be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results